Structure−Brain Exposure Relationships
Stephen A. Hitchcock, Lewis D. Pennington · Journal of Medicinal Chemistry · 2006
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTStructure−Brain Exposure RelationshipsStephen A. Hitchcock and Lewis D. PenningtonView Author Information Chemistry Research & Discovery, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799 Cite this: J. Med. Chem. 2006, 49, 26, 7559–7583Publication Date (Web):December 5, 2006Publication History Received30 May 2006Published online5 December 2006Published inissue 1 December 2006https://pubs.acs.org/doi/10.1021/jm060642ihttps://doi.org/10.1021/jm060642ireview-articleACS PublicationsCopyright © 2006 American Chemical SocietyRequest reuse permissionsArticle Views8747Altmetric-Citations544LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antibiotic resistance,Central nervous system,Permeability,Pharmaceuticals,Rodent models Get e-Alerts
Cited by 698 works. doi:10.1021/jm060642i
Authors
References
- Drug-like properties and the causes of poor solubility and poor permeability
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
- Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists
- Navigating chemical space for biology and medicine
- Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors
- NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
- Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design
- BLOOD-BRAIN BARRIER DRUG TARGETING: THE FUTURE OF BRAIN DRUG DEVELOPMENT
- Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
- Importance of P-glycoprotein at blood–tissue barriers